Roche displays the fruits of $9B in R&D spending

If Roche ($RHHBY) had a drug-development trading card, its stats would look something like this: R&D budget of $9 billion, with 72 development programs, 19 late-stage studies and 12 candidates for near-term approval. Top player in the line-up, at least for now? T-DM1, its on-the-verge-of-approval treatment for breast cancer. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.